New acne pill tested for Long-Term safety in 240 patients
NCT ID NCT06248008
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested the long-term safety of a daily pill called ASC40 (Denifanstat) in 240 people with moderate to severe acne who had already completed a previous phase 3 trial. Participants took the drug once daily for up to 40 weeks, with regular blood tests and checkups to monitor for side effects. The main goal was to see how many people experienced treatment-related problems, not to measure how well the drug cleared acne.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
ASC40 (Denifanstat) tablets
What this could lead to
If successful, this could confirm that ASC40 is safe for long-term use, potentially offering a new daily pill option for managing moderate to severe acne.
What could go wrong
This is an extension study focused on safety, not on proving how well the drug works. Side effects or lack of lasting benefit may limit its use.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACNE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Huashan Hospital Fudan University
Shanghai, Shanghai Municipality, 200000, China